BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology

Rhea-AI Summary

BioArctic (NASDAQ STOCKHOLM:B) announced a research and collaboration agreement with Eli Lilly to combine BioArctic's BrainTransporter technology with an undisclosed Lilly neurodegeneration drug candidate. BioArctic receives USD 30 million upfront, is eligible for up to USD 770 million in milestones, plus tiered mid-single digit royalties.

Lilly will handle global development and commercialization. This is BioArctic's fourth BrainTransporter collaboration, while it retains platform rights outside the four deals. The project uses an investigational agent, with no assurance of clinical success or regulatory approval.

Positive

• USD 30 million upfront payment from Lilly
• Eligibility for up to USD 770 million in milestone payments
• Tiered mid-single digit royalties on potential future global sales
• Lilly assumes full cost and responsibility for global development and commercialization
• Fourth collaboration validating BrainTransporter platform’s partnering appeal
• BioArctic retains BrainTransporter rights outside the four existing agreements

Negative

• All milestone and royalty revenues depend on successful development and approvals
• Investigational agent with no guarantee of efficacy, safety, or market approval
• BioArctic cedes development control to Lilly for this BrainTransporter project

News Market Reaction – B

-0.50%

-0.50% Session close to close

In the Jun 22 session, B declined 0.50%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights a Lilly collaboration with USD 30 million upfront and up to USD 770 mil...

Analysis

This announcement highlights a Lilly collaboration with USD 30 million upfront and up to USD 770 million in milestones, expanding BrainTransporter’s validation. Past news has often been well-received, but lengthy clinical development and approval risks remain key watchpoints.

Key Figures

Upfront payment: USD 30 million Milestone potential: USD 770 million Collaboration count: 4 agreements

3 metrics

Upfront payment USD 30 million Initial cash from Lilly-BioArctic BrainTransporter agreement

Milestone potential USD 770 million Maximum additional milestones under Lilly collaboration

Collaboration count 4 agreements Total BrainTransporter partnerships mentioned to date

Historical Context

5 past events · Latest: Jun 16 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 16	Robotics attitude survey	Neutral	+2.3%	Global survey on workplace and daily-life attitudes toward robots and automation.
Jun 12	Sustainability report	Positive	+3.1%	Release of 2025 sustainability report with improved safety and community metrics.
May 28	AGM outcomes	Neutral	+1.1%	AGM approvals including dividend, board elections, and new issuance authorization.
May 26	Anniversary milestone	Neutral	+3.5%	85th anniversary communication emphasizing technology-driven growth in claims services.
May 15	Partner revenue outlook	Positive	-5.9%	Eisai’s increased Leqembi sales projection and higher expected royalties to BioArctic.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has typically coincided with positive price moves, with one notable negative divergence on otherwise favorable partner guidance.

Key Terms

neurodegeneration, eu market abuse regulation, clinical development, health authority approval

4 terms

neurodegeneration medical

"an undisclosed Lilly drug candidate in neurodegeneration."

Neurodegeneration is the gradual damage and loss of nerve cells in the brain and nervous system, producing symptoms such as memory decline, impaired movement, or thinking problems. Think of it like electrical wiring in a house slowly fraying, which undermines how the system runs. For investors it matters because it drives demand for diagnostics, treatments and long-term care, influences regulatory risk and trial outcomes, and can significantly affect the value of health-care and biotech companies.

eu market abuse regulation regulatory

"pursuant to the EU Market Abuse Regulation."

A set of EU-wide rules that prevent cheating in financial markets by banning insider trading, market manipulation, and misleading disclosure; it also requires timely public release of key company information so everyone can play on a level field. For investors, it reduces the risk that prices are driven by secret deals or false signals, making markets fairer and more reliable for deciding when to buy or sell — like referees enforcing fair play in a game.

clinical development medical

"will successfully complete clinical development or gain health authority approval."

Clinical development is the process of testing a medical treatment in people to prove it is safe and works, moving from small early safety checks to larger trials that measure benefit and side effects. For investors it matters because each successful step reduces uncertainty and brings a product closer to regulatory approval and sales—like moving a prototype through road tests before mass production—while failures or delays can dramatically cut expected value.

health authority approval regulatory

"successfully complete clinical development or gain health authority approval."

Health authority approval is an official authorization from a government or recognized medical agency that a drug, medical device, vaccine, or treatment meets safety and effectiveness standards for use or sale. For investors it matters because approval is the key that allows a product to reach patients and generate revenue, while also reducing regulatory uncertainty and the risk of costly setbacks—think of it as a required green light before commercial launch.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, June 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the company has entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic's proprietary BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration. As part of the agreement, BioArctic will receive USD 30 million in upfront payment.

In addition to the upfront payment, BioArctic will be eligible to receive additional milestone payments of up to USD 770 million. BioArctic will also be entitled to tiered mid-single digit royalties on future global product sales if the product reaches the market. 

Under the collaboration, BioArctic will generate a new drug candidate combining the BrainTransporter technology with a Lilly proprietary molecule. Lilly will assume full responsibility for the global development and commercialization of the drug candidate and related products.

"I'm excited by today's announcement and proud that a large pharmaceutical company sees potential in our proprietary BrainTransporter technology. Lilly shares our ambition to do more for patients with severe neurological disorders, and this collaboration is a testament to that," said Gunilla Osswald, CEO at BioArctic.

This agreement is the fourth^[1] collaboration BioArctic has entered into with partners using the BrainTransporter technology. BioArctic retains all rights for use of the BrainTransporter platform outside of the scope of these four agreements. The BrainTransporter platform can be used in a multitude of different therapy areas for delivery of biologics and other modalities to the brain, giving BioArctic many potential future partnering opportunities. 

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agent will successfully complete clinical development or gain health authority approval.

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, on June 22, 2026, at 07.30 a.m. CET.

For further information, please contact: 
Oskar Bosson, VP Communications and IR
E-mail: oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80 

Jenny Ljunggren, External Communications and Investor Relations Manager
E-mail: jenny.ljunggren@bioarctic.com
Telephone: +46 76 013 86 08

About the BrainTransporter™ technology 

BioArctic's BrainTransporter technology is a technology for facilitating the passage of drugs into the brain using the transferrin receptor (TfR). Active transport of medicines across the blood-brain barrier can result in broader brain distribution enabling better efficacy, improved safety profile and dosing convenience. The technology is being applied to several in-house drug projects, as well as external collaborations, and could become part of future collaborations with other pharma companies.

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.se.

^[1] Previous agreements include a research evaluation agreement regarding BAN2802 with Eisai, a global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program and an option, collaboration and license agreement with Novartis.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/bioarctic-and-lilly-sign-research-and-collaboration-agreement-combining-lilly-compound-with-bioarcti,c4365925

The following files are available for download:

https://mb.cision.com/Main/9978/4365925/4160828.pdf

BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic’s BrainTransporter™ technology

 

View original content:https://www.prnewswire.com/news-releases/bioarctic-and-lilly-sign-research-and-collaboration-agreement-combining-lilly-compound-with-bioarctics-braintransporter-technology-302806106.html

SOURCE BioArctic

FAQ

What did BioArctic (B) announce on June 22, 2026 regarding Eli Lilly?

BioArctic announced a research and collaboration agreement with Eli Lilly for a potential neurodegeneration treatment. According to BioArctic, the deal combines its BrainTransporter technology with an undisclosed Lilly molecule, aiming to create a new drug candidate targeting severe neurological disorders.

How much upfront and milestone funding could BioArctic (B) receive from the Lilly collaboration?

BioArctic will receive USD 30 million upfront and could earn up to USD 770 million in milestones. According to BioArctic, it is also entitled to tiered mid-single digit royalties on future global sales if the investigational product successfully reaches the market.

What role will Lilly play in the BioArctic (B) BrainTransporter neurodegeneration program?

Lilly will take full responsibility for global development and commercialization of the new drug candidate. According to BioArctic, it will generate the BrainTransporter-enabled candidate, after which Lilly manages clinical development, regulatory interactions, and any potential worldwide product launches.

What is BioArctic's BrainTransporter technology in the context of the Lilly (B) agreement?

BrainTransporter is BioArctic’s proprietary platform for delivering biologics and other modalities to the brain. According to BioArctic, the technology can be applied across multiple therapy areas and this Lilly deal represents the fourth collaboration based on the BrainTransporter platform.

Does BioArctic (B) keep rights to its BrainTransporter platform after the Lilly deal?

BioArctic retains all BrainTransporter rights outside the scope of its four current collaborations, including the Lilly agreement. According to BioArctic, this leaves room for many future partnering opportunities across different therapy areas that may leverage the same delivery platform.

What risks does the BioArctic (B) and Lilly BrainTransporter collaboration involve for investors?

The collaboration centers on an investigational agent that may not succeed clinically or gain approval. According to BioArctic, there is no guarantee the candidate will complete development or reach the market, making milestones and royalties inherently uncertain.